Table 2.
Giani et al. [19] | YU et al. [32] | Kısaarslan et al. [31] | Khajezadeh et al. [30] | Zambrano et al. [33] | Singh et al. [34] | |
---|---|---|---|---|---|---|
Country of study | UK | China | Turkey | Iran | Colombia | India |
Cohort size | ||||||
• Total jSLE patients, N | 428 | 185 | 1107 | 146 | 90 | 53 |
• NP-jSLE patients, N (%) | 107 (25) | 64 (34.6) | 149 (13.5) | 41 (28) | 30 (33.3) | 27 (50.9) |
Female to male ratio | 5.4:1 | 5.9:1 | 7.7:1 | 3:1 | 5.4:1 | 2.8:1 |
Mean age (SD) | 12.2 (± 3.1) | 13.2 (± 3) | 12.8 | 10.2 (± 3) | 12.2 | 9.9 (± 3.2) |
Distribution of NP features (%) among NP-jSLE patients | ||||||
Central NS | 93 | 97 | 94.6 | 99.3 | 87 | 94.4 |
Peripheral NS | 7 | 3 | 5.4 | 0.7 | 13 | 5.6 |
Aseptic meningitis | 1.8 | 0 | 0.7 | 0.7 | N/A | 3.7 |
Acute confusional state | 6.5 | 12.5 | 33.6 | N/A | N/A | 7.5 |
Acute inflammatory demyelinating polyradiculoneuropathy (GBS) | 1 | 0 | 2 | N/A | 6 | N/A |
Autonomic disorders | 2.8 | 1.6 | 2 | N/A | N/A | N/A |
Anxiety disorders | 23.3 | 6.3 | 32.9 | N/A | N/A | 1.8 |
Cerebrovascular disease | 14.9 | 39 | 14.8 | 5.3 | 26 | 11.3 |
Cognitive dysfunction | 42 | 0 | 22.8 | 11.6 | N/A | 17 |
Cranial neuropathy | 5.6 | 1.6 | 3.4 | 0.7 | N/A | 1 |
Demyelinating syndrome | 1.8 | 3.1 | 2 | N/A | N/A | 1.8 |
Headache | 78.5 | 10.9 | 50 | 13 | 36 | 39.6 |
Movement disorders | 17.7 | 0 | 16.8 | 3.4 | 16 | 5.6 |
Mood disorders | 48.6 | 12.5 | 29.5 | 5.4 | N/A | 9.4 |
Myelopathy | 0.9 | 4.7 | 2.7 | N/A | N/A | N/A |
Psychosis | 9.3 | 21.9 | 17.4 | 2.1 | 13 | 9.4 |
Seizures | 19.6 | 84.4 | 38.3 | 9.5 | 50 | 35.8 |
Mononeuropathy | 8.4 | 3.1 | 2 | N/A | N/A | N/A |
Myasthenia gravis | 0 | 0 | 0 | N/A | N/A | N/A |
Plexopathy | 0.9 | 0 | 0 | N/A | N/A | N/A |
Polyneuropathy | 1.8 | 4.7 | 6 | N/A | N/A | N/A |
Only studies with sufficient clinical and demographic data have been included
jSLE juvenile systemic lupus erythematosus, NP neuropsychiatric, UK United Kingdom, SD standard deviation, NS nervous system, GBS Guillain-Barré syndrome, N/A not applicable